The comparative safety of bare-metal and drug-eluting intracoronary stents.
Bare-metal stents were a significant advance over percutaneous transluminal coronary angioplasty in the treatment of atherosclerotic coronary artery disease. However, bare-metal stents are plagued by a restenosis rate of approximately 30%. First-generation drug-eluting stents greatly reduce restenosis but are associated with a troublesome persistence of late thrombotic events. Stent thrombosis is a devastating clinical event, with high mortality rates. While the superior efficacy of drug-eluting stents is unquestioned, the relative safety of bare-metal and drug-eluting stents has been hotly debated. This article will address the safety of bare-metal and drug-eluting stents, and will describe current and future stent systems that promise to maintain current efficacy, while reducing thrombosis risk even further.